Participant flow

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) · Source last updated 2025-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.

   id

   FG000

   title

   Pemigatinib 13.5 mg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         16

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         17

      type

      Sponsor Decision

   4. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Moved to Commercial Supply of Investigational Drug

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Received First Dose of Chemotherapy for Stem Cell Transplant

   7. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Sponsor's Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         47

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         47

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

This study was conducted at 21 study centers in Belgium, Canada, France, Germany, Italy, Japan, Spain, United Kingdom, and the United States.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice